1. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
- Author
-
Bernadette Jaeger, Matthias W. Beckmann, Brigitte Rack, Christoph Scholz, Tobias Weissenbacher, Lukas Schwentner, A Schramm, Bernd Kost, Ines Schrader, Elisabeth Trapp, Julia Kathrin Jueckstock, Nikolaus DeGregorio, Peter A. Fasching, Thomas W. P. Friedl, Inga Bekes, Wolfgang Janni, Julia Neugebauer, Andreas Schneeweiss, Krisztian Lato, Miriam Deniz, Peter Widschwendter, and Ulrich Andergassen
- Subjects
Adult ,Bridged-Ring Compounds ,medicine.medical_specialty ,Receptor, ErbB-2 ,Antineoplastic Agents ,Triple Negative Breast Neoplasms ,Overweight ,Gastroenterology ,Deoxycytidine ,Disease-Free Survival ,Body Mass Index ,Young Adult ,Breast cancer ,610 Medical sciences Medicine ,Medizinische Fakultät ,Internal medicine ,medicine ,Humans ,Anthracyclines ,ddc:610 ,Obesity ,Aged ,Retrospective Studies ,Medicine(all) ,Gynecology ,Aged, 80 and over ,business.industry ,Hazard ratio ,nutritional and metabolic diseases ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Prognosis ,Gemcitabine ,Confidence interval ,Female ,Taxoids ,medicine.symptom ,Underweight ,business ,Body mass index ,Research Article - Abstract
Introduction: Obese breast cancer patients have worse prognosis than normal weight patients, but the level at which obesity is prognostically unfavorable is unclear. Methods: This retrospective analysis was performed using data from the SUCCESS A trial, in which 3754 patients with high-risk early breast cancer were randomized to anthracycline- and taxane-based chemotherapy with or without gemcitabine. Patients were classified as underweight/normal weight (body mass index (BMI)
- Published
- 2015